JP2006519762A5 - - Google Patents

Download PDF

Info

Publication number
JP2006519762A5
JP2006519762A5 JP2005501148A JP2005501148A JP2006519762A5 JP 2006519762 A5 JP2006519762 A5 JP 2006519762A5 JP 2005501148 A JP2005501148 A JP 2005501148A JP 2005501148 A JP2005501148 A JP 2005501148A JP 2006519762 A5 JP2006519762 A5 JP 2006519762A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
seq
peptide
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005501148A
Other languages
English (en)
Other versions
JP2006519762A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/032080 external-priority patent/WO2004032868A2/en
Publication of JP2006519762A publication Critical patent/JP2006519762A/ja
Publication of JP2006519762A5 publication Critical patent/JP2006519762A5/ja
Withdrawn legal-status Critical Current

Links

Claims (50)

  1. アルツハイマー病を治療するための、Aβ1-40のペプチド(配列番号１)のアミノ酸28-40に優先的に結合する抗体の有効量、および医薬的に許容される担体を含む医薬組成物であって、対象に投与される、前記組成物。
  2. 前記抗体が、Aβ1-40のペプチド(配列番号１)のアミノ酸39及び/又は40を含むエピトープに優先的に結合する、請求項１記載の医薬組成物。
  3. 前記抗体が、Aβ1-42ペプチドとAβ1-43ペプチドとの有意な交差反応性を示さない、請求項１又は２記載の医薬組成物。
  4. 前記抗体のFab断片が、200nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項１記載の医薬組成物。
  5. 前記抗体のFab断片が、１nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項１記載の医薬組成物。
  6. 前記抗体のFab断片が、200nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項２記載の医薬組成物。
  7. 前記抗体のFab断片が、１nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項２記載の医薬組成物。
  8. 前記抗体が、アミノ酸配列の配列番号４および６を含むモノクロナール抗体の、Aβ1-40のペプチド(配列番号１)への結合を競合的に阻害する、請求項１記載の医薬組成物。
  9. 前記抗体が、配列番号４および６のアミノ酸配列を含むモノクロナール抗体が結合するエピトープと同じエピトープに結合する、請求項１記載の医薬組成物。
  10. 前記抗体がモノクロナール抗体である、請求項１記載の医薬組成物。
  11. 前記抗体がヒト化(humanized)抗体である、請求項１記載の医薬組成物。
  12. 前記抗体がヒト抗体である、請求項１記載の医薬組成物。
  13. 対象のアミロイド斑の形成を阻害するための、Aβ1-40のペプチド(配列番号１)のアミノ酸28-40に優先的に結合する抗体の有効量、および医薬的に許容される担体を含む医薬組成物であって、当該対象に投与される、前記組成物。
  14. 前記抗体が、Aβ1-40のペプチド(配列番号１)のアミノ酸３９及び/又は４０を含むエピトープに優先的に結合する、請求項１３記載の医薬組成物。
  15. 前記抗体が、Aβ1-42ペプチドおよびAβ1-43ペプチドとの有意な交差反応性を示さない、請求項１３記載の医薬組成物。
  16. 前記抗体のFab断片が、200nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項１３記載の医薬組成物。
  17. 前記抗体のFab断片が、１nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項１３記載の医薬組成物。
  18. 前記抗体のFab断片が、200nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項１４記載の医薬組成物。
  19. 前記抗体のFab断片が、１nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項１４記載の医薬組成物。
  20. 前記抗体が、配列番号４および６のアミノ酸配列を含むモノクロナール抗体の、Aβ1-40のペプチド(配列番号１)への結合を競合的に阻害する、請求項１３記載の医薬組成物。
  21. 前記抗体が、配列番号４および６のアミノ酸配列を含むモノクロナール抗体が結合するエピトープと同じエピトープに結合する、請求項１３記載の医薬組成物。
  22. 前記抗体がモノクロナール抗体である、請求項１３記載の医薬組成物。
  23. 前記抗体がヒト化(humanized)抗体である、請求項１３記載の医薬組成物。
  24. 前記抗体がヒト抗体である、請求項１３記載の医薬組成物。
  25. 前記アミロイド斑が対象体の脳内にある、請求項１３記載の医薬組成物。
  26. 対象のアミロイド斑を減少させるための、Aβ1-40のペプチド(配列番号１)のアミノ酸28-40に優先的に結合する抗体の有効量、および医薬的に許容される担体を含む医薬組成物であって、当該対象に投与される、前記組成物。
  27. 前記抗体が、Aβ1-40のペプチド(配列番号１)のアミノ酸３９及び/又は４０を含むエピトープに優先的に結合する、請求項２６記載の医薬組成物。
  28. 前記抗体が、Aβ1-42ペプチドおよびAβ1-43ペプチドと有意な交差反応性を示さない、請求項２６記載の医薬組成物。
  29. 前記抗体のFab断片が、200nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項２６記載の医薬組成物。
  30. 前記抗体のFab断片が、１nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項２６記載の医薬組成物。
  31. 前記抗体のFab断片が、200nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項２７記載の医薬組成物。
  32. 前記抗体のFab断片が、１nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項２７記載の医薬組成物。
  33. 前記抗体が、配列番号４および６のアミノ酸配列を含むモノクロナール抗体の、Aβ1-40のペプチド(配列番号１)への結合を競合的に阻害する、請求項２６記載の医薬組成物。
  34. 前記抗体が、配列番号４および６のアミノ酸配列を含むモノクロナール抗体が結合するエピトープと同じエピトープに結合する、請求項２６記載の医薬組成物。
  35. 前記抗体がモノクロナール抗体である、請求項２６記載の医薬組成物。
  36. 前記抗体がヒト化(humanized)抗体である、請求項２６記載の医薬組成物。
  37. 前記抗体がヒトの抗体である、請求項２６記載の医薬組成物。
  38. 前記アミロイド斑が対象体の脳内にある、請求項２６記載の医薬組成物。
  39. 対象におけるアルツハイマー病の関連した症状の発症を遅延させるための、Aβ1-40ペプチド(配列番号１)のアミノ酸28-40に優先的に結合する抗体の有効量、および医薬的に許容される担体を含む医薬組成物であって、当該対象に投与される、前記組成物。
  40. 前記抗体が、Aβ1-40のペプチド(配列番号１)のアミノ酸３９及び/又は４０を含むエピトープに優先的に結合する、請求項３９記載の医薬組成物。
  41. 前記抗体が、Aβ1-42ペプチドおよびAβ1-43ペプチドと有意な交差反応性を示さない、請求項３９記載の医薬組成物。
  42. 前記抗体のFab断片が、200nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項３９記載の医薬組成物。
  43. 前記抗体のFab断片が、１nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項３９記載の医薬組成物。
  44. 前記抗体のFab断片が、200nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項４０記載の医薬組成物。
  45. 前記抗体のFab断片が、１nM以下の親和性にてAβ1-40のペプチド(配列番号１)に結合する、請求項４０記載の医薬組成物。
  46. 前記抗体が、配列番号４および６のアミノ酸配列を含むモノクロナール抗体の、Aβ1-40のペプチド(配列番号１)への結合を競合的に阻害する、請求項３９記載の医薬組成物。
  47. 前記抗体が、配列番号４および６のアミノ酸配列を含むモノクロナール抗体が結合するエピトープと同じエピトープに結合する、請求項３９記載の医薬組成物。
  48. 前記抗体がモノクロナール抗体である、請求項３９記載の医薬組成物。
  49. 前記抗体がヒト化(humanized)抗体である、請求項３９記載の医薬組成物。
  50. 前記抗体がヒト抗体である、請求項３９記載の医薬組成物。
JP2005501148A 2002-10-09 2003-10-09 アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法 Withdrawn JP2006519762A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41723202P 2002-10-09 2002-10-09
US44761103P 2003-02-13 2003-02-13
US46475403P 2003-04-22 2003-04-22
US48035303P 2003-06-20 2003-06-20
PCT/US2003/032080 WO2004032868A2 (en) 2002-10-09 2003-10-09 Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof

Publications (2)

Publication Number Publication Date
JP2006519762A JP2006519762A (ja) 2006-08-31
JP2006519762A5 true JP2006519762A5 (ja) 2006-11-16

Family

ID=32097078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005501148A Withdrawn JP2006519762A (ja) 2002-10-09 2003-10-09 アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法

Country Status (11)

Country Link
US (3) US20040146512A1 (ja)
EP (1) EP1633786A4 (ja)
JP (1) JP2006519762A (ja)
KR (1) KR20050071564A (ja)
AU (1) AU2003279216A1 (ja)
BR (1) BR0315157A (ja)
CA (1) CA2501945A1 (ja)
MX (1) MXPA05003621A (ja)
NO (1) NO20052220L (ja)
PL (1) PL377769A1 (ja)
WO (1) WO2004032868A2 (ja)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633786A4 (en) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
JP5042828B2 (ja) * 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
EP2289909B1 (en) 2005-11-30 2014-10-29 AbbVie Inc. Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
SG10201404801YA (en) * 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
CN101351476B (zh) 2005-12-12 2013-04-03 豪夫迈·罗氏有限公司 抗体可变区的糖基化
SI2177536T1 (sl) * 2006-03-30 2014-09-30 Glaxo Group Limited Protitelesa proti amiloidnemu peptidu beta
CL2007002070A1 (es) * 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
EP2104682B1 (en) 2007-01-11 2016-09-21 Michael Bacher Diagnosis and treatment of alzheimer's and other neurodementing diseases
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US9040045B2 (en) 2007-05-14 2015-05-26 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CA2695484C (en) 2007-08-20 2018-05-01 Glaxo Group Limited Production method of therapeutic proteins based on codon adaptation
CA2704064A1 (en) * 2007-09-13 2009-03-29 University Of Zurich Humanized antibodies against the .beta.-amyloid peptide
US20100239570A1 (en) * 2007-09-13 2010-09-23 Roger Nitsch Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
WO2009048538A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
SG10201505369QA (en) 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8921523B2 (en) * 2007-12-11 2014-12-30 Glaxo Group Limited Humanized anti-beta-amyloid antibodies
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
WO2009104736A1 (ja) * 2008-02-22 2009-08-27 財団法人ヒューマンサイエンス振興財団 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物
WO2010004434A2 (en) * 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
AU2009273387B9 (en) 2008-07-21 2015-06-11 Vivoryon Therapeutics N.V. Diagnostic antibody assay
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
ES2637245T3 (es) 2012-06-29 2017-10-11 Pfizer Inc. Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2
EP2897964A1 (en) 2012-09-20 2015-07-29 Pfizer Inc. Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014128585A1 (en) 2013-02-19 2014-08-28 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
ES2970063T3 (es) 2013-05-20 2024-05-24 Hoffmann La Roche Anticuerpos antirreceptor de transferrina y procedimientos de uso
AU2014305658A1 (en) 2013-08-05 2016-02-11 St. Vincent's Institute Of Medical Research An antibody therapy for amyloid beta disease
JP6425717B2 (ja) 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN113633768A (zh) 2013-12-17 2021-11-12 Mhs克尔创新有限责任公司 治疗脂肪组织积聚的组合物和方法
KR101886945B1 (ko) 2014-04-01 2018-08-08 화이자 인코포레이티드 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
AP2017009744A0 (en) 2014-08-06 2017-02-28 Pfizer Imidazopyridazine compounds
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX2017007491A (es) 2014-12-10 2018-05-04 Genentech Inc Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
HUE051898T2 (hu) 2015-06-17 2021-03-29 Pfizer Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
AR106230A1 (es) 2015-10-02 2017-12-27 Hoffmann La Roche Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN113332292A (zh) 2016-02-23 2021-09-03 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
MX2019000231A (es) 2016-07-01 2019-08-29 Pfizer Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas.
MX2019010756A (es) 2017-03-10 2020-01-20 Pfizer Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
CA3056027A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
JP7263266B2 (ja) 2017-06-22 2023-04-24 ファイザー・インク ジヒドロ－ピロロ－ピリジン誘導体
WO2019036725A2 (en) 2017-08-18 2019-02-21 Adrx, Inc. PEPTIDE INHIBITORS OF TAU AGGREGATION
ES2945165T3 (es) 2017-08-22 2023-06-28 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2019183636A1 (en) 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivaves
BR112020027055A2 (pt) * 2018-07-17 2021-04-06 Jiangsu Hengrui Medicine Co., Ltd. Anticorpo anti-abeta, fragmento de ligação ao antígeno do mesmo e aplicação dos mesmos
US20220031867A1 (en) 2018-10-04 2022-02-03 University Of Rochester Glymphatic delivery by manipulating plasma osmolarity
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4403112A (en) * 1981-05-18 1983-09-06 Modafferi Acoustical Systems, Ltd. Phase shift low frequency loudspeaker system
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4891268A (en) * 1984-03-26 1990-01-02 Metal Coatings International Inc. Coated metal substrates with anticorrosion coating composition
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5525339A (en) * 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) * 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5278299A (en) * 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114324D0 (en) * 1991-07-03 1991-08-21 Kontor Moulding Systems Ltd Injection moulding of thermoplastic polymers
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3144193A (en) * 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE213507T1 (de) * 1993-10-20 2002-03-15 Univ Duke Methode zur bindung von material an das beta- amyloid-peptid
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US5525126A (en) * 1994-10-31 1996-06-11 Agricultural Utilization Research Institute Process for production of esters for use as a diesel fuel substitute using a non-alkaline catalyst
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1996040885A2 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6221645B1 (en) * 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
AU7142796A (en) * 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6107029A (en) * 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
EP1006798A4 (en) * 1996-09-05 2003-03-05 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6221670B1 (en) * 1997-03-21 2001-04-24 Scios Inc. Methods to identify β-amyloid reducing agents
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
WO1998044955A1 (en) * 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
IL139095A0 (en) * 1998-05-21 2001-11-25 Univ Tennessee Res Corp Methods for amyloid removal using anti-amyloid antibodies
EP1173769B1 (en) * 1999-05-03 2007-02-28 Evotec AG Methods of diagnosing or treating alzheimer's disease
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
ES2312348T3 (es) * 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
US6255054B1 (en) * 1999-09-09 2001-07-03 Jacques Hugon Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US7485616B2 (en) * 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis
EP1172378A1 (en) * 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU1225702A (en) * 2000-09-19 2002-04-02 Evotec Neurosciences Gmbh Methods and compounds for treating brain amyloidosis
US6573276B2 (en) * 2001-05-09 2003-06-03 Boehringer Ingelheim Pharma Kg Muscarinic M1 agonist as an inhibitor of beta-amyloid (Aβ40 and Aβ42)-synthesis
JP2005500389A (ja) * 2001-08-17 2005-01-06 イーライ・リリー・アンド・カンパニー Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
WO2003039462A2 (en) * 2001-11-02 2003-05-15 Tanox, Inc. B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
CN100488982C (zh) * 2001-11-02 2009-05-20 迪尔基因国际有限公司 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法
AU2003223474B2 (en) * 2002-04-25 2008-09-04 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects
EP1633786A4 (en) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
JP5042828B2 (ja) * 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法

Similar Documents

Publication Publication Date Title
JP2006519762A5 (ja)
CA2501945A1 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
RU2005127429A (ru) Активная иммунизация для создания антител к растворимому а-бета
JP5419131B2 (ja) 治療的特性を有するβ１〜４２特異的モノクローナル抗体
JP2006516116A5 (ja)
JP2006516639A5 (ja)
DE602004009705T2 (de) Methoden der Verhinderung und Behandlung der Alzheimer'schen Krankheit
RU2526155C2 (ru) Способ лечения болезни альцгеймера
JP2003517461A5 (ja)
JP7071349B2 (ja) ピログルタメートアミロイド－βに対する抗体及びその使用
WO2005025516A3 (en) Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
JP2003523764A5 (ja)
JP2009511480A5 (ja)
WO2009065054A3 (en) Antibodies specific for the protofibril form of beta-amyloid protein
JP2009530423A5 (ja)
JP2012522754A5 (ja)
JP2005533001A5 (ja)
CO5640143A2 (es) Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico
AU2016362202B2 (en) Method for preventing or treating nosocomial pneumonia
AU2010267640A1 (en) N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for Alzheimer's disease
JP2004538477A5 (ja)
US7259232B1 (en) Preferred segments of neural thread protein
JP2008531719A5 (ja)
RU2005114355A (ru) Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций
CA2946929A1 (en) Treatment and prevention of alzheimer's disease (ad)